WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will parti ...

Market Performance - U.S. stocks showed mixed performance, with the Dow Jones index increasing by 0.54% to 49,261.60, while the NASDAQ fell by 0.62% to 23,437.73 and the S&P 500 dropped by 0.05% to 6,917.76 [1] - Industrial shares rose by 1.4% on Thursday, indicating strength in that sector [1] Sector Performance - Information technology stocks decreased by 1.4% on Thursday [2] Commodities - Oil prices increased by 1.8% to $56.98, while gold prices slightly decreased by 0.1% to $4,456.70. Silver fell by 3.6% to $74.820, and copper dropped by 1.7% to $5.7600 [6] European Market - European shares were mixed, with the eurozone's STOXX 600 declining by 0.27%, while Spain's IBEX 35 Index rose by 0.27%. London's FTSE 100 fell by 0.06%, Germany's DAX decreased by 0.08%, and France's CAC 40 increased by 0.06% [7] Asian Market - Asian markets closed lower, with Japan's Nikkei 225 down by 1.63%, Hong Kong's Hang Seng Index declining by 1.17%, China's Shanghai Composite slipping by 0.07%, and India's BSE Sensex falling by 0.92% [10] Company News - Flyexclusive Inc shares surged by 126% to $7.10 after being named an authorized Starlink Aviation dealer [9] - Enliven Therapeutics Inc shares increased by 54% to $23.81 following positive initial data from a clinical trial for chronic myeloid leukemia [9] - MoonLake Immunotherapeutics shares rose by 29% to $14.54 after receiving FDA feedback on its treatment for hidradenitis suppurativa [9] - Immuneering Corp shares dropped by 39% to $5.10 after announcing updated trial data for pancreatic cancer [9] - Acrivon Therapeutics Inc shares fell by 31% to $2.05 after releasing clinical data for endometrial cancer [9] - CorMedix Inc shares decreased by 23% to $8.00 following preliminary revenue results for Q4 and FY25 [9] Economic Indicators - U.S. initial jobless claims rose by 8,000 to 208,000, slightly below market expectations of 210,000 [3][12] - Nonfarm business sector labor productivity increased by 4.9% in Q3, following a revised 4.1% gain in the previous quarter [12] - Unit labor costs in the nonfarm business sector fell by 1.9% in Q3, contrasting with market expectations of a 1.0% increase [12] - The U.S. trade deficit narrowed to $29.4 billion in October, the smallest since June 2009, compared to a revised $48.1 billion in September [12]

Market Overview - U.S. stocks traded lower, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow decreased by 0.05% to 48,972.29, the NASDAQ declined by 0.57% to 23,448.86, and the S&P 500 fell by 0.14% to 6,911.57 [1] - Information technology stocks dipped by 1.4% on Thursday [2] - European shares were mostly lower, with the eurozone's STOXX 600 slipping 0.3% [7] - Asian markets closed lower, with Japan's Nikkei 225 falling 1.63% [9] Company Performance - Acuity Inc. (NYSE:AYI) reported fiscal first-quarter 2026 results, achieving a 20.2% year-over-year net sales growth to $1.14 billion, in line with analyst expectations. The adjusted EPS was $4.69, surpassing the consensus estimate of $4.59 [3] - Flyexclusive Inc. (NYSE:FLYX) shares surged 126% to $7.44 after being named an authorized Starlink Aviation dealer [8] - Enliven Therapeutics Inc. (NASDAQ:ELVN) shares increased by 59% to $24.55 following positive initial data from a Phase 1b clinical trial [8] - Nuvve Holding Corp. (NASDAQ:NVVE) shares rose by 46% to $5.11 after regaining Nasdaq compliance [8] - Immuneering Corp. (NASDAQ:IMRX) shares dropped 35% to $5.45 after announcing updated survival and safety data from a Phase 2a trial [8] - Acrivon Therapeutics Inc. (NASDAQ:ACRV) shares fell 29% to $2.10 after announcing clinical data related to endometrial cancer [8] - CorMedix Inc. (NASDAQ:CRMD) shares decreased by 25% to $8.33 following preliminary revenue results [8] Commodities - Oil prices increased by 1.9% to $57.03, while gold prices decreased by 0.6% to $4,436.20. Silver fell by 4.7% to $73.925, and copper dropped by 2.5% to $5.7120 [6]

Market Overview - U.S. stocks traded lower, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow decreased by 0.05% to 48,972.29, the NASDAQ declined by 0.57% to 23,448.86, and the S&P 500 fell by 0.14% to 6,911.57 [1] - Information technology stocks dipped by 1.4% on Thursday [2] - European shares were mostly lower, with the eurozone's STOXX 600 slipping 0.3% and various national indices showing slight declines [7] - Asian markets closed lower, with Japan's Nikkei 225 falling 1.63% and Hong Kong's Hang Seng Index declining 1.17% [9] Company Performance - Acuity Inc. reported fiscal first-quarter 2026 results with a 20.2% year-over-year net sales growth to $1.14 billion, aligning with analyst expectations. The adjusted EPS was $4.69, surpassing the consensus estimate of $4.59 [3] - Flyexclusive Inc. shares surged 126% to $7.44 after being named an authorized Starlink Aviation dealer [8] - Enliven Therapeutics Inc. shares increased by 59% to $24.55 following positive initial data from a clinical trial for chronic myeloid leukemia [8] - Nuvve Holding Corp. shares rose by 46% to $5.11 after regaining Nasdaq compliance [8] - Immuneering Corp. shares dropped 35% to $5.45 after announcing updated survival and safety data from a clinical trial [8] - Acrivon Therapeutics Inc. shares fell 29% to $2.10 after announcing clinical data and plans for EU expansion [8] - CorMedix Inc. shares decreased by 25% to $8.33 following preliminary revenue results [8] Commodities - Oil prices increased by 1.9% to $57.03, while gold prices decreased by 0.6% to $4,436.20. Silver fell by 4.7% to $73.925, and copper dropped by 2.5% to $5.7120 [6]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Aclarion, Inc. (ACON) is up 38% at $7.94 [3] - A SPAC III Acquisition Corp. (ASPC) is up 31% at $21.41 [3] - Nuvve Holding Corp. (NVVE) is up 23% at $4.32 [3] - Acrivon Therapeutics, Inc. (ACRV) is up 20% at $3.55 [3] - PMGC Holdings Inc. (ELAB) is up 16% at $6.76 [3] - Serina Therapeutics, Inc. (SER) is up 14% at $2.73 [3] - Regencell Bioscience Holdings Limited (RGC) is up 13% at $60.00 [3] - One Stop Systems, Inc. (OSS) is up 11% at $8.75 [3] - Anixa Biosciences, Inc. (ANIX) is up 9% at $3.60 [3] - Globus Medical, Inc. (GMED) is up 7% at $96.99 [3] Premarket Losers - Immuneering Corporation (IMRX) is down 23% at $6.34 [4] - Genelux Corporation (GNLX) is down 12% at $2.95 [4] - Erasca, Inc. (ERAS) is down 11% at $4.55 [4] - Phathom Pharmaceuticals, Inc. (PHAT) is down 10% at $16.10 [4] - Acurx Pharmaceuticals, Inc. (ACXP) is down 9% at $2.62 [4] - Evolution Metals & Technologies Corp. (EMAT) is down 8% at $17.34 [4] - Revolution Medicines, Inc. (RVMD) is down 7% at $95.14 [4] - Cardio Diagnostics Holdings, Inc. (CDIO) is down 7% at $2.59 [4] - Vestis Corporation (VSTS) is down 6% at $6.42 [4] - WORK Medical Technology Group LTD (WOK) is down 6% at $2.75 [4]

Core Insights - Acrivon Therapeutics has reported significant progress in its clinical pipeline, particularly with ACR-368 for endometrial cancer, showing a 39% overall response rate (ORR) in monotherapy and 44% in subjects with ≤2 prior lines of therapy [1][5] - The company is advancing ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, with initial Phase 1 data indicating favorable tolerability and tumor shrinkage in various cancer types [1][2] - Acrivon has nominated ACR-6840, a potential first-in-class CDK11 inhibitor, for preclinical development, with an IND submission planned for Q4 2026 [1][3] ACR-368 Program - The ongoing Phase 2b trial of ACR-368 has shown a confirmed overall response rate (cORR) of 52% in serous endometrial cancer subjects with ≤2 prior lines of therapy, and 67% in biomarker-positive (BM+) subjects [1][5] - Arm 3 of the trial will enroll up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requiring a tumor biopsy, with enrollment completion expected in Q4 2026 [1][5] - A Phase 3 confirmatory protocol for ACR-368 in combination with anti-PD-1 therapy has been submitted to the FDA, with global trial readiness anticipated by mid-2026 [1][2] ACR-2316 Development - Initial data from the Phase 1 dose escalation study of ACR-2316 (N=33) demonstrated favorable tolerability and tumor shrinkage at doses ≥120 mg, including confirmed partial responses in endometrial cancer and unconfirmed responses in small cell lung cancer (SCLC) [1][2][5] - The study has established two weekly oral dosing regimens, with a bi-weekly regimen initiated to enhance dosing flexibility [1][5] ACR-6840 Nomination - ACR-6840 has been nominated as the next preclinical development candidate, targeting CDK11, with an IND submission expected in Q4 2026 [1][3][12] - The development of ACR-6840 is based on its potential to achieve optimal on-target pathway effects, leveraging the company's proprietary AP3 platform [1][12] Financial Position - As of December 31, 2025, Acrivon reported preliminary cash, cash equivalents, and investments of approximately $119 million, expected to fund operations into Q2 2027 [8][9]

Company Performance - AZZ Inc reported adjusted earnings of $1.52 per share, exceeding market estimates of $1.47 per share [1] - The company's sales reached $425.746 million, surpassing expectations of $418.164 million [1] - AZZ shares increased by 2.1% to $112.09 in pre-market trading following the earnings report [1] Notable Stock Movements - CIMG Inc gained 33.3% to $1.44 after securing approximately $124 million in commercial contracts [4] - ECD Automotive Design Inc rose 26.4% to $0.59 due to talks for strategic deals valued between $2 million and $10 million [4] - Acrivon Therapeutics Inc increased by 22.1% to $3.60, announcing a clinical update on its ongoing studies [4] - Nuvve Holding Corp gained 17.1% to $4.11 after a previous 60% rise [4] - RenovoRx Inc surged 16.8% to $1.18 in pre-market trading [4] - Serina Therapeutics Inc rose 16.4% to $2.82 after a 15% increase on Wednesday [4] - Super League Enterprise Inc increased by 11.2% to $0.68 following an asset purchase agreement [4] - Northrop Grumman Corp gained 6.8% to $616.26, influenced by a potential increase in the military budget [4] Declining Stocks - Immuneering Corp fell 20.7% to $6.61 after announcing updated trial data [4] - Erasca Inc decreased by 14% to $4.45 after a previous 42% rise [4] - Phathom Pharmaceuticals Inc dropped 13.7% to $15.60 following a $130 million public offering announcement [4] - United Microelectronics Corp fell 6.3% to $8.37 after a previous 10% increase [4]

Group 1: Biotechnology and Healthcare Companies Performance - Several biotechnology and healthcare companies experienced notable gains in after-hours trading due to clinical updates, financial results, and upcoming industry presentations [1] Group 2: ALX Oncology Holdings Inc. - ALX Oncology Holdings Inc. (ALXO) surged 10.17% to $1.30 after announcing positive data from a Phase 2 trial of its lead candidate, evorpacept, in combination with rituximab and lenalidomide for patients with indolent B-cell non-Hodgkin lymphoma [2] - The findings are scheduled to be presented on December 7, 2025, at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida [2] Group 3: Globus Medical, Inc. - Globus Medical, Inc. (GMED) climbed 9.34% to $99.00 following preliminary unaudited sales results, reporting fourth-quarter 2025 sales of approximately $823.2 million, a 25.2% increase year-over-year [3] - Full-year 2025 sales are expected to reach $2.936 billion, representing a 16.5% increase from the prior year [3] - The company set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share in the range of $4.30 to $4.40 [3] Group 4: Acrivon Therapeutics, Inc. - Acrivon Therapeutics, Inc. (ACRV) rose 6.44% to $3.14 after announcing plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026 [4] Group 5: Other Companies - AnaptysBio, Inc. (ANAB) advanced 1.75% to $46.00 after confirming that CEO Daniel Faga will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [5] - Omeros Corp. (OMER) added 4.47% to $14.72 without any new corporate updates [6] - EUDA Health Holdings Limited (EUDA) increased 3.73% to $2.50 after amending its warrant agreement with Streeterville Capital, LLC [6] - TherapeuticsMD, Inc. (TXMD) rose 5.34% to $2.15 in after-hours trading, with no new announcements reported [6] - Pyxis Oncology, Inc. (PYXS) gained 4.93% to $1.49 without any fresh news [7]

Group 1 - Humacyte, Inc. (HUMA) has gained approximately 12.4% year-to-date, outperforming the average gain of 7.6% for Medical stocks [4] - The Zacks Rank for Humacyte, Inc. is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The consensus estimate for Humacyte's full-year earnings has increased by 15.9% over the past quarter, reflecting improved analyst sentiment [3] Group 2 - Humacyte, Inc. is part of the Medical - Biomedical and Genetics industry, which has an average gain of 18.6% this year, indicating that HUMA is slightly underperforming its industry [5] - Acrivon Therapeutics, Inc. (ACRV), another Medical stock, has outperformed the sector with a return of 24.9% year-to-date [4] - The Medical - Drugs industry, to which Acrivon belongs, has gained 3.1% this year and is ranked 90 among 141 stocks [6]

Core Viewpoint - Acrivon Therapeutics is set to provide clinical data for its lead programs ACR-368 and ACR-2316 on January 8, 2026, highlighting advancements in precision medicine through its proprietary platform [1][4][7] Group 1: Company Overview - Acrivon Therapeutics is a clinical stage biotechnology company focused on discovering and developing precision medicines using its Generative Phosphoproteomics AP3 platform [3] - The AP3 platform enables unbiased interpretation and quantification of drug-regulated pathway activity levels in intact cells, generating terabytes of data for actionable insights [3] - Acrivon aims to overcome traditional drug discovery limitations by rapidly designing differentiated compounds and advancing them into clinical development [3] Group 2: Clinical Programs - ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is currently in a Phase 2b trial for endometrial cancer and has received Fast Track designation from the FDA [4] - The ACR-2316 program, a WEE1/PKMYT1 inhibitor, is in Phase 1 trials, with initial clinical activity and dose proportionality observed in early cohorts [5][7] - Upcoming updates will include interim clinical data from the ACR-368 study and initial data from the ACR-2316 study, along with a new preclinical development candidate [7]